383 related articles for article (PubMed ID: 38655136)
1. Targeted therapy for multiple myeloma: an overview on CD138-based strategies.
Riccardi F; Tangredi C; Dal Bo M; Toffoli G
Front Oncol; 2024; 14():1370854. PubMed ID: 38655136
[TBL] [Abstract][Full Text] [Related]
2. [The Significance of CD319 and CD269 in the Detection of Immunophenotyping and Minimal Residual Disease in Multiple Myeloma Patients].
Chu B; Wang YT; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Bao L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1195-1202. PubMed ID: 34362502
[TBL] [Abstract][Full Text] [Related]
3. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.
Soh KT; Tario JD; Hahn T; Hillengass J; McCarthy PL; Wallace PK
Cytometry B Clin Cytom; 2021 Jul; 100(4):497-508. PubMed ID: 33017079
[TBL] [Abstract][Full Text] [Related]
4. Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.
Jung O; Trapp-Stamborski V; Purushothaman A; Jin H; Wang H; Sanderson RD; Rapraeger AC
Oncogenesis; 2016 Feb; 5(2):e202. PubMed ID: 26926788
[TBL] [Abstract][Full Text] [Related]
5. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
6. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
7. A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma.
Braunstein M; Weltz J; Davies F
Expert Rev Hematol; 2021 Apr; 14(4):377-389. PubMed ID: 33769179
[TBL] [Abstract][Full Text] [Related]
8. CAR T cells targeting options in the fight against multiple myeloma.
Nicolini F; Bravaccini S; Mazza M; Gruszka AM; Tazzari M; MartÍn-Antonio B; Juan M; Ibrahim T; Maltoni R; Martinelli G; Cerchione C
Panminerva Med; 2021 Mar; 63(1):37-45. PubMed ID: 32955187
[TBL] [Abstract][Full Text] [Related]
9. The development of potential antibody-based therapies for myeloma.
Sherbenou DW; Behrens CR; Su Y; Wolf JL; Martin TG; Liu B
Blood Rev; 2015 Mar; 29(2):81-91. PubMed ID: 25294123
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
Zamagni E; Tacchetti P; Pantani L; Cavo M
Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
12. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in multiple myeloma: when, where, and for who?
Verkleij CPM; Korst CLBM; van de Donk NWCJ
Curr Opin Oncol; 2020 Nov; 32(6):664-671. PubMed ID: 32852308
[TBL] [Abstract][Full Text] [Related]
14. [Expression and clinical significance of Notch1 on the membrane of bone marrow CD38(+)CD138(+) plasma cells in the patients with multiple myeloma].
Zhao YR; Fu R; Guan J; Gao S; Liu H; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Wu YH; Song J; Wang HQ; Xing LM; Wang J; Li LJ; Shao ZH
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):274-7. PubMed ID: 22781716
[TBL] [Abstract][Full Text] [Related]
15. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
16. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.
Wu D; Guo X; Su J; Chen R; Berenzon D; Guthold M; Bonin K; Zhao W; Zhou X
Biochim Biophys Acta; 2015 Feb; 1853(2):338-47. PubMed ID: 25450979
[TBL] [Abstract][Full Text] [Related]
17. Syndecan‑1 expression is an independent favourable prognostic marker in oesophageal adenocarcinoma and represents a potential therapeutic target.
Akca D; Simon A; Buettner R; Bruns C; Schroeder W; Zander T; Gebauer F; Quaas A
Oncol Lett; 2023 Aug; 26(2):356. PubMed ID: 37545626
[TBL] [Abstract][Full Text] [Related]
18. [Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels].
Wang YZ; Lu J; Hao L; Chang Y; He LL; Huang XJ; Liu YR
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):272-278. PubMed ID: 28468086
[No Abstract] [Full Text] [Related]
19. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
Ak I; Gulbas Z
Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapies for Multiple Myeloma.
Leow CC; Low MSY
J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33922567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
